SCHEMBL5564573

SCHEMBL5564573

Cc1ccccc1C(=O)c1cnc(NCCCNS(=O)(=O)c2cccc(F)c2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MAPK11 Q15759 3/20 0.40
MAPK14 Q16539 3/20 0.40
ERN1 O75460 2/20 0.40
ABL1 P00519 2/20 0.40
RAF1 P04049 2/20 0.40
FGFR1 P11362 2/20 0.40
BRAF P15056 2/20 0.40
FLT3 P36888 2/20 0.40
MAPK8 P45983 2/20 0.40
NTRK2 Q16620 2/20 0.40
HIPK1 Q86Z02 2/20 0.40
MAP3K20 Q9NYL2 2/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568923 0.98 KAT6A (0.43) KAT6ASMN1; SMN2MAPK11MAPK14MAPK13
SCHEMBL5564727 0.97 KAT6A (0.42) KAT6ASMN1; SMN2MAPK11MAPK14MAPK13
SCHEMBL5569779 0.90 MAPK13 (0.45) SMN1; SMN2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5564570 0.90 ALDH1A1 (0.43) SMN1; SMN2
SCHEMBL5564149 0.89 MAPK13 (0.53) MAPK11MAPK14MAPK13MAPK12
SCHEMBL5565863 0.89 MAPK13 (0.45) MAPK11MAPK14MAPK13MAPK12
SCHEMBL5569804 0.88 MAPK13 (0.45) SMN1; SMN2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5564366 0.88 MAPK13 (0.42) SMN1; SMN2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5567832 0.87 ALDH1A1 (0.46) SMN1; SMN2MAPK11MAPK14MAPK13MAPK12
SCHEMBL5568715 0.87 ALDH1A1 (0.47) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480976-B1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-09-19 EP disclosed
EP-1480976-A1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-12-01 EP disclosed
US-6686381-B2 COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA HOFFMANN-LA ROCHE INC. 2004-02-03 US disclosed
US-20030225141-A1 THIAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. 2003-12-04 US disclosed
WO-2003072577-A1 THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225141-A1 THIAZOLE DERIVATIVES SLC5A1, GPR119, TAS1R1 KAT6A 3812/4885SMN1; SMN2 2375/4885MAPK11 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.